**Press Release**

**ANGELINI VENTURES INVESTS IN US ANTI-EPILEPSY TECHNOLOGY**

*Angelini Ventures, the venture capital company of Angelini Industries, has invested US$6 million in the US startup Cadence Neuroscience, which is developing a new continuous neuromodulation system in collaboration with Mayo Clinic for the treatment of drug-resistant epilepsy.*

**Rome –25 May 2023** – Angelini Ventures, the international venture capital company of Angelini Industries, has invested **US$6 million in Cadence Neuroscience, a US startup** that is developing, in collaboration with Mayo Clinic researchers, a new neuromodulation therapy for the treatment of focal drug-resistant epilepsy in paediatric and adult patients. The treatment is based on software capable of detecting epilepsy-related signals recorded in the electroencephalogram (EEG) and countering them with targeted electrical stimulation to eliminate or reduce seizures.

The US$6 million investment by Angelini Ventures is part of new total funding of **US$26 million**, representing the Series B round, i.e., the second growth stage for Cadence Neuroscience, which aims to complete the preliminary clinical studies and obtain approval from the Food and Drug Administration (FDA). The round was led by Angelini Lumira Bioscience Fund (the North American fund created by Lumira Ventures and Angelini Ventures) and involved other new investors: F-Prime Capital, LivaNova PLC, Angelini Ventures, Spectrum Financial Services, and Mayo Clinic, along with JAZZ Venture Partners, which led the initial Series A round. Gerry Brunk from Lumira Ventures and Kevin Chu from F-Prime Capital will join the Board of Directors of Cadence Neuroscience.

*"Investments like this, which we are making with Angelini Ventures,"* ***says Sergio Marullo di Condojanni, CEO of Angelini Industries****, "fully align with our growth strategy in the neurological disorders area and are in perfect harmony with the long-term vision that is written into the DNA of an entrepreneurial group like ours. In addition to being a potential development opportunity, this investment fully meets our mission, which is primarily to take care of patients and improve their quality of life."*

*"The technology developed by Cadence Neuroscience has the potential to become a benchmark for the treatment of drug-resistant epilepsy and other brain-related conditions,"* **notes Paolo Di Giorgio, CEO of Angelini Ventures**. "*This investment is part of our strategy to focus internationally on innovative and highly technological players in the life sciences, digital health, and biotechnology sectors. Our goal is to identify, finance, and implement solutions that innovate traditional healthcare models*."

With investments totalling €300 million, €70 million of which is already planned, in Europe, North America, and Israel, with a particular focus on brain health and market segments targeting women, children, and elderly people, Angelini Ventures is aligned with the growth and innovation strategy of Angelini Industries, a multinational industrial group with 5,800 employees and **€2 billion in revenues** in the healthcare, consumer goods, and industrial technology sectors.

**Cadence Neuroscience** is a startup based in Redmond, near Seattle, founded in 2017. It has developed a new technology for the treatment of focal drug-resistant epilepsy in paediatric and adult patients based on research conducted by the neurology and neurosurgery team at Mayo Clinic, led by neurologist and epilepsy specialist Gregory Worrell.

Cadence Neuroscience has developed software capable of identifying precise epilepsy-related signals recorded in the EEG and modulating them through precise electrical impulses with the aim of eliminating or reducing seizures. The software is installed in a small permanent neural implant that generates continuous cortical electrical stimulation modulated on the basis of the brain impulses monitored by the software itself. In this way, the system developed by Cadence Neuroscience aims to offer targeted and personalised therapy.

\*\*\*

**Angelini Industries** isa multinational industrial group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries represents a solid and diversified industrial reality that employs approximately 5,800 employees and operates in 21 countries around the world with revenues of over 2 billion euros, generated in the healthcare, industrial technology and consumer goods sectors.

A targeted investment strategy for growth; constant commitment to research and development; deep knowledge of markets and business sectors, make Angelini Industries one of the Italian companies of excellence in the sectors in which it operates.  The group is committed to reducing its environmental impact and finding increasingly advanced solutions in terms of circular economy, adopting the most advanced standards in health and safety of workers and the most rigorous processes to ensure maximum quality by verifying the entire supply chain: from supplier certification to the control of raw materials, to the production process, to the finished product and packaging, up to spot checks at the point of sale.  For over 100 years, the Angelini family has been leading the evolution of Angelini Industries with an entrepreneurial style typical of Italian family capitalism.  To learn more visit: [www.angeliniindustries.com](http://www.angeliniindustries.com)

**Media contacts:**

**Angelini Industries**

Alessandra Favilli – Group Chief Communication Officer

[alessandra.favilli@angeliniholding.com](mailto:alessandra.favilli@angeliniholding.com) – [press@angeliniindustries.com](mailto:press@angeliniindustries.com)

**SEC Newgate Italia**

Daniele Pinosa – [daniele.pinosa@secnewgate.it](mailto:daniele.pinosa@secnewgate.it) – tel. +39 3357233872

Fausta Tagliarini – [fausta.tagliarini@secnewgate.it](mailto:fausta.tagliarini@secnewgate.it) – tel. +39 3476474513

Daniele Murgia – [daniele.murgia@secnewgate.it](mailto:daniele.murgia@secnewgate.it) – tel. +39 3384330031